Events after the reporting date

BRAIN Biotech AG has signed an exclusive technology license agreement with Akribion Therapeutics GmbH for the genome editing nuclease G-dase E® for the pharmaceutical sector. BRAIN Biotech can receive up to € 92.3 million in R&D and commercial milestone payments from Akribion for granting these exclusive rights for use in the pharmaceutical area. Moreover, BRAIN Biotech is entitled to license fees from future net revenues. The payment structure is based on progress in clinical development and future commercialization successes. BRAIN staff who were assigned to the business unit managed as Akribion Genomics will be transferred to Akribion Therapeutics GmbH as part of a transfer of operations.

The genome editing nuclease G-dase E® forms part of the proprietary CRISPR-Cas genome editing nuclease portfolio of BRAIN Biotech AG, and was developed as part of the company’s BioIncubator pipeline for highly innovative projects. BRAIN Biotech will continue to develop this portfolio of nucleases outside the pharmaceutical sector on its own initiative, harness it as a technological differentiator in customer projects, and offer it to external parties for licensing.

Prof. Dr. Wiltrud Treffenfeldt stepped down from her position as an ordinary member of the Supervisory Board of BRAIN Biotech AG for personal reasons with effect from 3 October 2024. Prof. Dr. Treffenfeldt had been a member of the Supervisory Board of BRAIN Biotech AG since October 2020.

No further significant events or developments of material importance to the company’s financial position and performance have occurred since the 30 September 2024 balance sheet date.